Phase 1Completed
Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome (3-Star)
A Phase Ib Multi-Center, Double-Blind, Randomized, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability and Immunogenicity of ACI-24 in Adults With Down Syndrome
- Sponsor
- AC Immune SA (Industry)
- Enrolment
- 20 enrolled
- Conditions
- Down Syndrome
- Interventions
- ACI-24 low dose; ACI-24 high dose; Placebo
- Ages
- adults
- Registry
- NCT02738450
From the registry
The purpose of this study is to test in adults with Down Syndrome the safety, tolerability and immunogenicity of a vaccine, ACI-24.
Primary outcomes
- Antibody Titer (Serum Anti-Aβ1-42 Free IgG) - Mean Absolute Value